Deep Medicine Acquisition Corp. (DMAQ)
| Previous Close | 10.21 |
| Open | 10.21 |
| Bid | 10.18 x 1200 |
| Ask | 10.23 x 2900 |
| Day's Range | 10.21 - 10.21 |
| 52 Week Range | 9.70 - 10.99 |
| Volume | |
| Avg. Volume | 24,953 |
| Market Cap | 167.783M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.03 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
UPDATE 1-China's Chijet to merge with new SPAC at lower valuation than prior deal
Chijet Motor Co on Wednesday agreed to go public in the United States through a merger with a blank-check company that gave the China-based automaker a 37% lesser valuation than what it had secured in another deal that was terminated. The deal with special purpose acquisition company (SPAC) Jupiter Wellness Acquisition Corp values Chijet at $1.6 billion, less than a month after Deep Medicine Acquisition Corp called off its $2.55 billion deal. Before calling off the deal with the automaker, Deep Medicine had twice extended the due diligence period.
- GlobeNewswire
Deep Medicine Acquisition Corp. Announces Appointment of a New Director
New York, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Deep Medicine Acquisition Corp. (Nasdaq: DMAQ) (the “Company”) announced today the appointment of Mr. John Chiang as a member to its board of directors, effective October 15, 2022. Mr. Chiang has been serving as a member of the board of directors of Apollo Medical Holdings, Inc. since January 2019 and on the corporate advisory boards of Pasadena Private Lending, LLC since February 2019, Adept Urban since January 2021, and Calyx Peak Companies since
- GlobeNewswire
Deep Medicine Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination
New York, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Deep Medicine Acquisition Corp. (Nasdaq: DMAQ) (the “Company”), announced today that an aggregate of $1,265,000 has been deposited into the Company’s trust account for its public shareholders, representing $0.10 per public share, which enables the Company to extend the period of time it has to consummate its initial business combination by three months from October 29, 2022 to January 29, 2023 (the “Extension”). The Extension is the first of up to
